Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number

PLoS ONE

Volumn 5, Issue 1, 2010, Pages

  Andrews, Joseph ^a   Kennette, Wendy ^a   Pilon, Jenna ^a,b   Hodgson, Alexandra ^a,b   Tuck, Alan B ^a,b   Chambers, Ann F ^a,b   Rodenhiser, David I ^a,b,c  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b WESTERN UNIVERSITY   (Canada)

^c CHILDREN S HEALTH RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CARCINOGENESIS; DNA METHYLATION; EPIGENETICS; GENE DELETION; GENE EXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; KARYOTYPING; MICROARRAY ANALYSIS; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENETIC EPIGENESIS; GENETICS; GENOME; METASTASIS; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENOME; HUMANS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77952499379     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008665     Document Type: Article

References (52)

1. Xu J, Chambers AF, Tuck AB, Rodenhiser DI (2008) Molecular cytogenetic characterization of human breast cancer cell line MDA-MB-468 and its variant 468LN, which displays aggressive lymphatic metastasis. Cancer Genetics and Cytogenetics 181: 1-7.
2. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
3. Sadikovic B, Andrews J, Carter D, Robinson J, Rodenhiser DI (2008) Genomewide H3K9 histone acetylation profiles are altered in benzopyrene treated MCF7 breast cancer cells. J Biol Chem 283: 4051-4060.
4. Rodenhiser DI, Andrews J, Kennette W, Sadikovic B, Mendlowitz A, et al. (2008) Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res 10: R62.
5. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
6. Weigelt B, Hu Z, He X, Livasy C, Carey LA, et al. (2005) Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 65: 9155-9158.
7. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, et al. (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98: 1183-1192.
8. Welch DR (2004) Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 6: 61-64.
9. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
10. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, et al. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3: 537-549.
11. Esteller M (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
12. Esteller M (2007) Cancer epigenomics: DNA methylomes and histonemodification maps. Nat Rev Genet 8: 286-298.
13. Carter NP (2007) Methods and strategies for analyzing copy number variation using DNA microarrays. Nat Genet 39: S16-21.
14. Yuan E, Haghighi F, White S, Costa R, McMinn J, et al. (2006) A single nucleotide polymorphism chip-based method for combined genetic and epigenetic profiling: validation in decitabine therapy and tumor/normal comparisons. Cancer Res 66: 3443-3451.
15. Juric D, Bredel C, Sikic BI, Bredel M (2007) Integrated high-resolution genomewide analysis of gene dosage and gene expression in human brain tumors. Methods Mol Biol 377: 187-202.
16. Chi B, deLeeuw RJ, Coe BP, Ng RT, MacAulay C, et al. (2008) MD-SeeGH: a platform for integrative analysis of multi-dimensional genomic data. BMC Bioinformatics 9: 243.
17. Sadikovic B, Yoshimoto M, Al-Romaih K, Maire G, Zielenska M, et al. (2008) In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS ONE 3: e2834.
18. Vantyghem SA, Allan AL, Postenka CO, Al-Katib W, Keeney M, et al. (2005) A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes. Clin Exp Metastasis 22: 351-361.
19. Clark SJ, Harrison J, Paul CL, Frommer M (1994) High sensitivity mapping of methylated cytosines. Nucleic Acids Res 22: 2990-2997.
20. Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18: 1427-1431.
21. Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, et al. (2003) Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res 31: 3497-3500.
22. Cailleau R, Olive M, Cruciger QV (1978) Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14: 911-915.
23. Zhang RD, Fidler IJ, Price JE (1991) Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 11: 204-215.
24. http://www.affymetrix.com/products-services/research-solutions/methods/ copy-number-loh.affx.
25. http://ccr.coriell.org/Sections/Collections/NHGRI/Yoruba.aspx?PgId =128&coll= HG.
26. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A genee-xpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
27. Feng Y, Sun B, Li X, Zhang L, Niu Y, et al. (2006) Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat.
28. Woelfle U, Cloos J, Sauter G, Riethdorf L, Janicke F, et al. (2003) Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 63: 5679-5684.
29. Schumacher A, Kapranov P, Kaminsky Z, Flanagan J, Assadzadeh A, et al. (2006) Microarray-based DNA methylation profiling: technology and applications. Nucleic Acids Res 34: 528-542.
30. Rodenhiser DI (2008) Epigenetic contributions to cancer metastasis. Clin Exp Metastasis.
31. Rodenhiser D, Mann M (2006) Epigenetics and human disease: translating basic biology into clinical applications. Cmaj 174: 341-348.
32. Momparler RL (2005) Epigenetic therapy of cancer with 5-aza-2′-deoxycytidine (decitabine). Semin Oncol 32: 443-451.
33. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
34. Johnson N, Speirs V, Curtin NJ, Hall AG (2008) A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer. Breast Cancer Res Treat 111: 55-63.
35. Fadlelmola FM, Zhou M, de Leeuw RJ, Dosanjh NS, Harmer K, et al. (2008) Sub-megabase resolution tiling (SMRT) array-based comparative genomic hybridization profiling reveals novel gains and losses of chromosomal regions in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma cell lines. Mol Cancer 7: 2.
36. de Tayrac M, Etcheverry A, Aubry M, Saikali S, Hamlat A, et al. (2009) Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer 48: 55-68.
37. Margareto J, Leis O, Larrarte E, Pomposo IC, Garibi JM, et al. (2009) DNA Copy Number Variation and Gene Expression Analyses Reveal the Implication of Specific Oncogenes and Genes in GBM. Cancer Invest. pp 1.
38. Chari R, Lockwood WW, Coe BP, Chu A, Macey D, et al. (2006) SIGMA: a system for integrative genomic microarray analysis of cancer genomes. BMC Genomics 7: 324.
39. Feinberg AP, Vogelstein B (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92.
40. Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, et al. (2005) Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37: 853-862.
41. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, et al. (2004) A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. Cancer Res 64: 5527-5534.
42. Veeck J, Bektas N, Hartmann A, Kristiansen G, Heindrichs U, et al. (2008) Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours. Breast Cancer Res 10: R82.
43. Pulukuri SM, Rao JS (2006) CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene 25: 4559-4572.
44. Lodygin D, Hermeking H (2006) Epigenetic silencing of 14-3-3sigma in cancer. Semin Cancer Biol 16: 214-224.
45. Horie-Inoue K, Inoue S (2006) Epigenetic and proteolytic inactivation of 14-3-3sigma in breast and prostate cancers. Semin Cancer Biol 16: 235-239.
46. Pusztai L (2006) Chips to bedside: incorporation of microarray data into clinical practice. Clin Cancer Res 12: 7209-7214.
47. London Regional Genome Centre; http://www.lrgc.ca.
48. Affymetrix; http://www.affymetrix.com.
49. Affymetrix Nettfix tool; http://www.affymetrix.com/analysis/index.affx.
50. Primerquest Software Integrated DNA Technologies; http://www.idtdna.com/ SciTools/SciTools.aspx.
51. Exonprimer Software; http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer. html.
52. International HapMap Project; http://www.hapmap.org.